Author:
Huang Miaoen,Wang Tianji,Wang Yinghao,Deng Qingyan,Chen Jinjun,Li Li,Luo Hui,Lu Yingnian
Abstract
Biopeptides from Sipunculus nudus were reported with good ACE inhibitory activity, and the tripeptide SRP was one with the highest ACE inhibition rate. However, the disadvantage of short half-life limited the development of peptide drugs. Moreover, the distinct mechanism of the peptide inhibiting ACE remained unknown. Thus, in this study, a sustained release formulation of SRP-PLGA-MS was designed and prepared. Its long-lasting antihypertensive effect as well as improvement of vascular pathomorphology was verified in spontaneously hypertensive rat (SHR). In addition, the anti-oxidant activity of SRP in human umbilical vein endothelial cells (HUVECs) was evaluated. The results showed that SRP inhibited the production of ROS and NO, which involve the NADPH oxidase, and Keap1/Nrf2 signaling pathway. This study demonstrated that SRP-PLGA-MS had the potential to develop sustained-release drugs for hypertension treatment.
Reference50 articles.
1. Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19·1 million participants;Zhou;Lancet,2017
2. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries;Chow;JAMA,2013
3. Mechanisms of vascular remodeling in hypertension;Humphrey;Am J Hypertens,2021
4. Oxidative stress and hypertension;Griendling;Circ Res,2021
5. Oxidative stress, GTPCH1, and endothelial nitric oxide synthase uncoupling in hypertension;Wu;Antioxid Redox Signal,2021